As long as it's listed, it has a chance with the pending FDA trials. It looks good. Usually delisting takes a while, look at DCTH, it was supposed to face delisting at the beginning of the month, but it evaded it. Unless anyone has seen something concrete saying a delisting is imminent, I wouldn't worry too much.